Literature DB >> 7864587

Evaluation of a transgenic mouse model for alpha-1-antitrypsin (AAT) related liver disease.

R Ali1, S Perfumo, C della Rocca, L Amicone, L Pozzi, P McCullagh, H Millward-Sadler, Y Edwards, S Povey, M Tripodi.   

Abstract

We have attempted to produce a transgenic mouse model of the neonatal liver disease associated with the human PIZ allele. Analysis of a number of transgenic mouse lines carrying either a normal human PIM gene construct or the mutant Z is reported. Using isoelectric focusing analysis of plasma from transgenic mice, we have shown that the human AAT proteins produced in mice are processed in a similar way to their counterparts in humans. By comparing the level of M and Z mRNA in liver with the levels of M and Z proteins in plasma we have inferred that, as in humans, the mutant protein tends to accumulate within the hepatocyte. Accumulation of Z protein has also been demonstrated by immunocytochemistry. Two of the M transgenic lines produce such high levels of the human protein that it, like the Z protein, accumulates as globules. Histological features of livers from 116 mice of different ages and genotypes were examined: 37 non-transgenic, 62 Z transgenic (23 low expressing and 39 high expressing) and 17 M transgenic mice, all high expressing. Cirrhosis or fibrosis was not seen in any animal and we were unable to find any evidence for neonatal liver disease. Some necrosis was seen in all genotypes and this increased significantly with age with one Z line showing significantly more frequent necrosis than any other group. This line, the highest expressing Z line, was back crossed onto 7 different genetic backgrounds but no major differences between the back crosses with respect to liver disease were observed. The mouse model we have developed is compared with other transgenic Z mouse models; none of these is representative of human neonatal liver disease. Our view is that the transgenic animals generated in these experiments may be most useful for investigating the liver manifestations that almost invariably occur in ZZ adults. Alteration of additional factors other than accumulation of Z protein, for example inactivation of the endogenous mouse genes or some environmental challenge, might produce a mouse model with more relevance to neonatal liver disease.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7864587     DOI: 10.1111/j.1469-1809.1994.tb00728.x

Source DB:  PubMed          Journal:  Ann Hum Genet        ISSN: 0003-4800            Impact factor:   1.670


  4 in total

1.  A novel model and molecular therapy for Z alpha-1 antitrypsin deficiency.

Authors:  Gillian L McNab; Timothy R Dafforn; Alice Wood; Elizabeth Sapey; Robert A Stockley
Journal:  Mamm Genome       Date:  2011-11-11       Impact factor: 2.957

2.  Antisense oligonucleotide treatment ameliorates alpha-1 antitrypsin-related liver disease in mice.

Authors:  Shuling Guo; Sheri L Booten; Mariam Aghajan; Gene Hung; Chenguang Zhao; Keith Blomenkamp; Danielle Gattis; Andrew Watt; Susan M Freier; Jeffery H Teckman; Michael L McCaleb; Brett P Monia
Journal:  J Clin Invest       Date:  2013-12-20       Impact factor: 14.808

3.  Z α1-antitrypsin confers a proinflammatory phenotype that contributes to chronic obstructive pulmonary disease.

Authors:  Samuel Alam; Zhenjun Li; Carl Atkinson; Danny Jonigk; Sabina Janciauskiene; Ravi Mahadeva
Journal:  Am J Respir Crit Care Med       Date:  2014-04-15       Impact factor: 21.405

4.  Using antisense technology to develop a novel therapy for α-1 antitrypsin deficient (AATD) liver disease and to model AATD lung disease.

Authors:  Shuling Guo; Sheri L Booten; Andrew Watt; Luis Alvarado; Susan M Freier; Jeffery H Teckman; Michael L McCaleb; Brett P Monia
Journal:  Rare Dis       Date:  2014-03-12
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.